# ‚öîÔ∏è STRATEGIC REVIEWS & DIRECTION - MASTER DOCUMENTATION

**Date**: January 28, 2025  
**Status**: üéØ **STRATEGIC GUIDANCE CONSOLIDATED**  
**Consolidated From**: 5 strategic review documents (now archived)

---

## üìö TABLE OF CONTENTS

1. [Executive Summary](#executive-summary)
2. [Core Strategic Framework](#core-strategic-framework)
3. [Agent Landscape & Coordination](#agent-landscape--coordination)
4. [Strategic Gap Analysis](#strategic-gap-analysis)
5. [Individual Agent Reviews](#individual-agent-reviews)
6. [Key Principles & Decision Framework](#key-principles--decision-framework)
7. [Action Items & Next Steps](#action-items--next-steps)

---

## üéØ EXECUTIVE SUMMARY

### **The Core Strategic Issue**

**We conflated mechanism alignment (what the system does) with outcome prediction (what doctors need).**

Our system can:
- ‚úÖ **Rank drugs correctly** (100% Top-5 accuracy)
- ‚úÖ **Compute pathway scores** (DDR, MAPK, PI3K, etc.)
- ‚úÖ **Find relevant trials** (eligibility-based matching)
- ‚ùå **Cannot predict outcomes** (r=0.037 correlation with PFS/OS)

**The Hard Truth**: Our efficacy scores are **biologically plausible** but not **clinically predictive**.

### **Strategic Direction**

**Option A: Mechanism Alignment Tool** (Current State)
- "This drug targets the pathways disrupted in your tumor"
- Guideline-aligned recommendations
- Decision support, not decision making
- **Value**: Automation of clinical reasoning

**Option B: Outcome Prediction Tool** (Future Goal)
- "You have X% probability of responding to this drug"
- Calibrated efficacy‚Üíoutcome predictions
- Requires clinical validation
- **Value**: Personalized treatment selection

**Current Reality**: We built Option A but need to validate if it can become Option B.

---

## üèóÔ∏è CORE STRATEGIC FRAMEWORK

### **Mechanism Alignment vs Outcome Prediction**

| Claim Type | Allowed | Not Allowed |
|------------|---------|-------------|
| **Mechanism alignment** | ‚úÖ "This drug targets pathways disrupted in your tumor" | ‚ùå "This drug will improve your survival" |
| **Pathway computation** | ‚úÖ "High DDR pathway burden (0.88)" | ‚ùå "High DDR predicts PARP response" |
| **Trial ranking** | ‚úÖ "Trial matches your pathway profile" | ‚ùå "You're more likely to respond to this trial" |
| **Evidence grading** | ‚úÖ "Strong literature on mechanism" | ‚ùå "Clinically proven to work" |
| **Treatment awareness** | ‚úÖ "Appropriate for first-line chemotherapy" | ‚ùå "Will improve chemotherapy response" |

### **What We Know (Validated)**

1. **Drug ranking works** (100% Top-5 accuracy)
   - System recommends clinically appropriate drugs
   - Matches NCCN guidelines
   - This is mechanism alignment working

2. **Pathway computation works**
   - Gene‚Üípathway mapping is correct (MBD4‚ÜíDDR verified)
   - Pathway scores compute correctly
   - 7D mechanism vectors work structurally

3. **Outcome prediction doesn't work** (r=0.037)
   - Efficacy scores essentially random for PFS/OS
   - This is the gap we need to address

### **What We Don't Know (Unvalidated)**

1. **Can mechanism alignment predict outcomes?**
   - We assume: High DDR ‚Üí better PARP response
   - We haven't tested this assumption
   - Zo2's work will answer this

2. **Will biomarkers help?**
   - TMB/HRD/MSI should improve predictions
   - But we don't know by how much
   - Zo2's Phase 1 will answer this

3. **Will weight tuning help?**
   - Assuming the formula CAN predict outcomes
   - If the formula is structurally wrong, tuning won't help
   - Zo2's Phase 2 depends on Phase 1 results

---

## üë• AGENT LANDSCAPE & COORDINATION

### **Current Agent Status**

| Agent | Task | Status | Timeline | Dependency |
|-------|------|--------|----------|------------|
| **Zo** | MBD4+TP53 Analysis | ‚úÖ Complete | Done | None |
| **Zo2** | S/P/E Calibration | üîÑ Phase 1 | 1-2 weeks | None |
| **Trial Matching** | Mechanism Fit + Resistance | üìã Approved | 3 days | None (independent) |
| **Food Validation** | Nutritional Support | ‚úÖ 95% Complete | Alignment needed | None |
| **MM Doctrines** | TCell/TCF1/TLS/TOX | ‚ö†Ô∏è Hold | 24 weeks planned | Wait for others |

### **Key Insights**

1. **These workstreams are independent**:
   - Zo: Already done (mechanism alignment works)
   - Zo2: Improving outcome prediction (separate problem)
   - Trial Matching: Wiring existing services (no outcome prediction)
   - Food Validation: Companion to drug recs (parallel output)

2. **Priority Order**:
   - **Immediate**: Zo2 Phase 1, Trial Matching Day 1, Food Validation alignment
   - **Next Sprint**: Zo2 Phase 2 (if checkpoint passes), Trial Matching Days 2-3
   - **Following Sprint**: MM Doctrines Phase 0 test suite only

---

## üìä STRATEGIC GAP ANALYSIS

### **The 5 Strategic Gaps**

#### **Gap 1: Efficacy Scores ‚â† Outcome Prediction**

**What We Say**: "PARP inhibitors rank #1-2 (efficacy_score >0.80)"

**What Benchmarks Show**: Efficacy scores have r=0.037 correlation with PFS (essentially random)

**The Gap**: 
- We're computing **mechanism alignment** (does this drug target the patient's pathways?)
- We're NOT computing **outcome probability** (will this patient respond to this drug?)

**Strategic Impact**: ‚ö†Ô∏è **HIGH** - The entire drug prediction section is mechanism-based, not outcome-based

#### **Gap 2: No Validation of Pathway‚ÜíOutcome Link**

**What We Say**: "Pathway scores show high DDR burden (>0.70)"

**What Benchmarks Show**: No validation that high DDR pathway burden ‚Üí better PARP response

**The Gap**: We have formulas for pathway scores, but ZERO evidence these formulas correlate with patient outcomes

**Strategic Impact**: ‚ö†Ô∏è **HIGH** - All pathway-based predictions are unvalidated

#### **Gap 3: Mechanism Fit Ranking is Unvalidated**

**What We Say**: "Mechanism fit = cosine similarity between pathway vector and trial MoA vector"

**What Benchmarks Show**: No validation that mechanism fit ranking improves trial outcomes

**The Gap**: We're ranking trials by mechanism alignment, but have no evidence this ranking correlates with patient outcomes

**Strategic Impact**: ‚ö†Ô∏è **MEDIUM** - Trial ranking is better than random, but mechanism fit contribution (30%) is unvalidated

#### **Gap 4: Classification Bug Hides Progression Data**

**What We Say**: "Resistance Detection" - DNA repair capacity tracking

**What Benchmarks Show**: 0 progression events detected (PFS_STATUS parsing bug)

**The Gap**: We claim to detect resistance/progression, but can't even PARSE progression data correctly

**Strategic Impact**: ‚ö†Ô∏è **MEDIUM** - Fixable bug, but blocking validation

#### **Gap 5: Validation Set Bias May Mask Real Performance**

**What We Say**: "66 patients with SAE features extracted"

**What Benchmarks Show**: Testing with lowest mutation counts (2-18 mutations), may not represent typical patients

**The Gap**: We're testing on "easy" patients, but real MBD4+TP53 patients have complex mutation profiles (50-100+ mutations)

**Strategic Impact**: ‚ö†Ô∏è **MEDIUM** - Validation set doesn't represent target population

### **What We CAN Deliver (Validated)**

1. **Variant Annotation** ‚úÖ
   - Evo2 scoring works (sequence disruption)
   - Insights bundle works (functionality, essentiality)
   - Evidence integration works (ClinVar, literature)

2. **Pathway Computation** ‚úÖ
   - Pathway scores compute correctly
   - Gene‚Üípathway mapping is accurate (MBD4‚ÜíDDR verified)
   - 7D mechanism vector construction works

3. **Drug Ranking** ‚úÖ (100% Top-5)
   - Recommends clinically appropriate drugs
   - Aligns with NCCN guidelines
   - Matches what patients actually receive

4. **Trial Matching** ‚úÖ (Eligibility-based)
   - Finds relevant trials
   - Eligibility scoring works
   - Mechanism fit computation works (unvalidated)

### **What We CANNOT Deliver (Unvalidated)**

1. **Outcome Prediction** ‚ùå
   - Efficacy scores don't predict PFS/OS
   - No validated probability of response
   - No validated probability of resistance

2. **Comparative Effectiveness** ‚ùå
   - "Drug A is better than Drug B for this patient"
   - No validation that higher efficacy scores ‚Üí better outcomes

3. **Resistance Prediction** ‚ùå
   - DNA repair capacity formula unvalidated
   - Resistance detection unvalidated
   - CA-125 kinetics unvalidated

4. **Trial Outcome Prediction** ‚ùå
   - Mechanism fit ranking unvalidated
   - No evidence that higher mechanism fit ‚Üí better trial outcomes

---

## üìã INDIVIDUAL AGENT REVIEWS

### **1. Zo (AYESHA Agent) - ‚úÖ COMPLETE**

**Status**: ‚úÖ **COMPLETE** - MBD4+TP53 mechanism alignment done

**What Was Delivered**:
- MBD4+TP53 mechanism alignment is done
- Drug ranking is validated (PARP #1-3, Platinum #4)
- Pathway scores are computed correctly

**What to Communicate**:
- "Mechanism alignment works. Outcome prediction is separate work (Zo2)."
- "Our system finds drugs that target patient pathways. Whether that predicts outcomes is being validated."

**Don't Overclaim**:
- Don't say "efficacy score 0.80 means 80% response"
- Say "mechanism alignment score 0.80 means strong biological rationale"

---

### **2. Zo2 (S/P/E Agent) - üîÑ PHASE 1**

**Status**: üîÑ **PHASE 1** - Biomarker integration ready to execute

**Goal**: Improve r=0.037 correlation to r=0.15+

**Critical Decision Framework**: **VALIDATE PHASE 1 FIRST. DO NOT PROCEED IN PARALLEL.**

**Phase 1 Tasks** (Week 1):
1. Create biomarker_extractor.py
2. Update api_client.py for tumor_context
3. Fix PFS_STATUS parsing
4. Run benchmark with biomarkers
5. Compute correlation improvement
6. **CHECKPOINT**: Report results before proceeding

**Decision Point** (After Week 1):
- r > 0.10 ‚Üí Proceed to Phase 2
- r < 0.10 ‚Üí STOP. Investigate why.

**Realistic Expectations**:

| Phase | Zo2's Target | Realistic Target | Notes |
|-------|-------------|------------------|-------|
| Phase 1 | r=0.10-0.15 | r=0.05-0.10 | Biomarkers help but won't transform |
| Phase 2 | r=0.25-0.35 | r=0.10-0.20 | Weight tuning has diminishing returns |
| Phase 3 | r=0.35-0.50 | r=0.15-0.25 | Treatment adjustment is complex |

**What Would Be a Win?**:
- r > 0.25: Moderate correlation, potentially useful ‚Üí Proceed to calibration
- r = 0.15-0.25: Weak correlation, needs work ‚Üí Investigate
- r < 0.15: Negligible correlation ‚Üí Pivot to different approach

---

### **3. Trial Matching Agent - üìã APPROVED**

**Status**: ‚úÖ **APPROVED** - Proceed with implementation

**Goal**: Wire mechanism fit ranking to trial search (independent of Zo2)

**Key Clarification**: This work is **INDEPENDENT** of Zo2's outcome calibration. Mechanism fit doesn't predict outcomes; it ranks trials by pathway alignment.

**Verification**: "80% complete" claim is **accurate**
- ‚úÖ `mechanism_fit_ranker.py` EXISTS (275 lines)
- ‚úÖ `resistance_prophet_service.py` EXISTS (689 lines)
- ‚úÖ `pathway_to_mechanism_vector.py` EXISTS
- ‚ö†Ô∏è Mechanism fit NOT in trial response (needs wiring)
- ‚ö†Ô∏è Validation scripts missing

**Timeline**: 12-16h realistic (add 30% buffer to 9-13h claimed)

**Success Thresholds (MVP)**:
- Top-3 accuracy: ‚â•0.70 (not ‚â•0.80)
- MRR: ‚â•0.65 (not ‚â•0.75)
- High risk AUROC: ‚â•0.65 (not ‚â•0.70)

**Clarifications Needed**:
1. MoA coverage report in validation output
2. Baseline handling documentation in resistance output
3. Integration test with AYESHA analysis

---

### **4. Food Validation Agent - ‚ö†Ô∏è ALIGNMENT REQUIRED**

**Status**: ‚ö†Ô∏è **APPROVED WITH ALIGNMENT REQUIRED**

**Goal**: Nutritional support recommendations alongside drug efficacy predictions

**What's Good** ‚úÖ:
- Integration with AYESHA flow (parallel output in CompleteCare)
- Treatment line intelligence (genuine differentiation)
- Biomarker gates (HRD/TMB/MSI targeting)
- S/P/E framework alignment (same formula as drugs)

**What Needs Alignment** ‚ö†Ô∏è:

1. **"Precision Medicine-Grade" Overclaim**
   - **Current**: "Transformed generic AI recommendations into **precision medicine-grade** food validation"
   - **Should Be**: "Transformed generic AI recommendations into **mechanism-aligned, treatment-aware** food recommendations"

2. **"Efficacy Score" Terminology**
   - **Current**: `"efficacy_score": 0.72`
   - **Should Be**: `"alignment_score": 0.72` or `"suitability_score": 0.72`

3. **Missing Validation Disclaimer**
   - **Current**: "Evidence tier: SUPPORTED"
   - **Should Add**: "Evidence tiers reflect literature strength, not clinical outcome validation. SUPPORTED means there's published research on the mechanism, not that the food has been clinically proven to improve cancer outcomes."

**Action Items** (Before Deployment):
1. Rename `efficacy_score` ‚Üí `alignment_score` in API response
2. Add limitations section to documentation
3. Revise "precision medicine-grade" ‚Üí "mechanism-aligned, treatment-aware"
4. Add disclaimer to frontend display

---

### **5. MM Doctrines Agent - ‚ö†Ô∏è HOLD**

**Status**: ‚ö†Ô∏è **HOLD - NEEDS SCOPE REDUCTION**

**Goal**: T-Cell Recruitment Engineering, TCF1 Engineering, TLS Engineering, TOX Doctrine

**The Problem**: 24-week, 18-endpoint plan when other agents are delivering in days/weeks

**Scope Breakdown**:
- Proxy classifiers: 3 endpoints (6 weeks)
- Design tools: 12 endpoints (6 weeks)
- TOX endpoints: 7 endpoints (4 weeks)
- Orchestrators: 3 endpoints (4 weeks)
- Feedback infrastructure: 2 weeks
- Spatial integration: 4 weeks
- **Total**: 18+ endpoints, 24 weeks

**External Dependencies** (High Risk):
- CIBERSORT/TIMER2: ‚ùå Not integrated
- NetMHCpan: ‚ùå Not integrated
- Spatial data (Visium): ‚ùå Not integrated
- TCGA data: ‚ö†Ô∏è Scripts exist, no service

**Recommended Approach: Phase-Gated MVP**

**Phase 0: Foundation (1 week)** - ALREADY MOSTLY DONE
- ‚úÖ Mechanism vector conversion (done)
- ‚úÖ Pathway score extraction (done)
- ‚è≥ Create known biology test suite

**Phase 1A: ONE Proxy Classifier (2 weeks)** - Pick one:
- T-Cell Recruitment (if MD Anderson partnership is active)
- TLS Readiness (if MSK data is available)
- TCF1/Tox (if deconvolution not needed)

**Checkpoint after Phase 1A**:
- Does proxy classifier achieve r > 0.25?
- If yes ‚Üí Continue
- If no ‚Üí Investigate before building more

**Priority Order**:
1. **Immediate**: Zo2 Phase 1, Trial Matching, Food Validation alignment
2. **Next Sprint**: Zo2 Phase 2 (if checkpoint passes), Trial Matching Days 2-3
3. **Following Sprint**: MM Doctrines Phase 0 test suite only
4. **Later**: MM Doctrines Phase 1A (ONE proxy classifier)

---

## üéØ KEY PRINCIPLES & DECISION FRAMEWORK

### **1. Validate Before Optimize**

Don't tune weights until you know the formula can work.

**The Wrong Approach**:
```
Week 1: Add biomarkers
Week 2-3: Tune weights
Week 4: Tune treatment adjustment
‚Üí Hope correlation improves
```

**The Right Approach**:
```
Week 1: Add biomarkers (Phase 1)
‚Üí CHECKPOINT: Did correlation improve?
   - If r > 0.10: Proceed to Phase 2
   - If r < 0.10: STOP. Investigate why.

Week 2: Analyze results
‚Üí CHECKPOINT: Where is the signal?
   - If DDR‚ÜíPFS correlation exists: Tune DDR weight
   - If no DDR‚ÜíPFS correlation: Weight tuning won't help

Week 3-4: Calibrate (only if Phase 1 shows promise)
```

### **2. Checkpoint-Driven Development**

Stop and assess after each phase. Don't assume next phase will help.

**Example**: Zo2 Phase 1 Checkpoint
```python
def phase_1_checkpoint():
    """Decide whether to proceed to Phase 2."""
    
    # 1. Measure correlation improvement
    r_before = 0.037  # Known baseline
    r_after = compute_correlation_with_biomarkers()
    
    if r_after > 0.10:
        return "PROCEED"
    elif r_after > 0.05:
        return "INVESTIGATE"
    else:
        return "STOP"
    
    # 2. Analyze WHERE improvement came from
    # - Did TMB-high patients have better IO boost correlation?
    # - Did BRCA+ patients have better PARP correlation?
    # - Did HRD-high patients have better DDR correlation?
```

### **3. Honest Communication**

Say "mechanism alignment" when you mean mechanism alignment.
Say "outcome prediction" only when validated.

**What We CAN Say (Honest)**:
> "Based on MBD4 germline loss and TP53 somatic mutation, this patient has:
> - High DNA damage response pathway burden (DDR: 0.88)
> - Mechanism alignment with PARP inhibitors (olaparib, niraparib)
> - Eligibility for DDR-targeting clinical trials
> 
> This suggests PARP inhibitors and platinum chemotherapy are biologically appropriate options to discuss with the oncology team."

**What We CANNOT Say (Overpromise)**:
> ‚ùå "This patient has 85% probability of responding to olaparib."
> ‚ùå "Olaparib will extend progression-free survival by 6 months."
> ‚ùå "This patient should enroll in NCT123456 because it has the highest mechanism fit."

### **4. Know When to Pivot**

If Phase 1 shows no improvement, investigate before proceeding.
Sometimes the answer is "this approach won't work."

---

## üìã ACTION ITEMS & NEXT STEPS

### **Immediate (This Week)**

1. **Zo2: Execute Phase 1** (Week 1)
   - Create biomarker_extractor.py
   - Update api_client.py for tumor_context
   - Fix PFS_STATUS parsing
   - Run benchmark with biomarkers
   - Compute correlation improvement
   - **CHECKPOINT**: Report results before proceeding

2. **Trial Matching: Start Day 1** (3-4h)
   - Wire mechanism fit to trial search
   - Test with MBD4+TP53 example
   - Add MoA coverage report requirement
   - Add baseline handling documentation
   - Add integration test with AYESHA

3. **Food Validation: Alignment Changes**
   - Rename `efficacy_score` ‚Üí `alignment_score` in API response
   - Add limitations section to documentation
   - Revise "precision medicine-grade" ‚Üí "mechanism-aligned, treatment-aware"
   - Add disclaimer to frontend display

4. **MM Doctrines: ‚ùå DO NOT START**
   - Wait for other agents to complete
   - Create test suite and MVP definition when ready

### **Next Sprint (Weeks 2-3)**

5. **Zo2: Phase 2** (if Phase 1 checkpoint passes)
   - Only proceed if r > 0.10
   - Focus on pathways that showed improvement
   - Disease-specific weight tuning

6. **Trial Matching: Days 2-3**
   - Enhance resistance prophet
   - Validation scripts
   - Integration testing

7. **MM Doctrines: Start Phase 0 test suite only**
   - Known biology tests
   - No implementation yet

### **Following Sprint (Weeks 4-5)**

8. **MM Doctrines: Start ONE proxy classifier (Phase 1A)**
   - Pick one: TLS or TCF1 (less external dependencies)
   - Skip deconvolution initially
   - Checkpoint after first classifier

### **Medium-Term (This Month)**

9. **Validate Pathway‚ÜíOutcome Link**
   - Find cohort with DDR pathway burden + PARP outcomes
   - Test: Does high DDR ‚Üí better PARP response?
   - If not, pathway scores are descriptive only

10. **Validate Mechanism Fit Ranking**
    - Find cohort with trial enrollment + outcomes
    - Test: Does mechanism fit ‚Üí better trial outcomes?
    - If not, reduce mechanism fit weighting

### **Long-Term (This Quarter)**

11. **Build Outcome Prediction Model**
    - Train on patient outcomes, not just mechanism alignment
    - Use SAE features as input (when TRUE SAE ready)
    - Validate with held-out cohort

12. **Calibrate Mechanism Alignment Scores**
    - Map mechanism alignment ‚Üí outcome probability
    - Requires outcome data (response, PFS, OS)
    - May need disease-specific calibration

---

## üéØ SUCCESS METRICS

### **Zo2 (S/P/E Calibration)**

| Outcome | Interpretation | Next Steps |
|---------|----------------|------------|
| r > 0.25 | Moderate correlation, potentially useful | Proceed to calibration, clinical validation |
| r = 0.15-0.25 | Weak correlation, needs work | Investigate, consider model changes |
| r < 0.15 | Negligible correlation | Pivot to different approach |

### **Trial Matching**

| Metric | MVP Threshold | Stretch Goal |
|--------|---------------|--------------|
| Top-3 accuracy | ‚â•0.70 | ‚â•0.80 |
| MRR | ‚â•0.65 | ‚â•0.75 |
| High risk AUROC | ‚â•0.65 | ‚â•0.70 |

### **Food Validation**

| Criterion | Status |
|-----------|--------|
| Mechanism-aligned recommendations | ‚úÖ Met |
| Treatment-aware filtering | ‚úÖ Met |
| Biomarker gates | ‚úÖ Met |
| Transparent scoring | ‚úÖ Met |
| Evidence grading | ‚úÖ Met |
| Honest framing | ‚ö†Ô∏è Pending (add limitations section) |

### **MM Doctrines**

| Phase | Deliverable | Success Criteria |
|-------|-------------|------------------|
| Phase 0 | Test suite | Known biology tests pass |
| Phase 1A | ONE proxy classifier | r > 0.25 (checkpoint) |
| Phase 1B | Second classifier | Only if Phase 1A succeeds |
| Phase 2 | Design tools | Only if Phase 1 validates |

---

## üìä SUMMARY TABLE

| Agent | Status | Priority | Timeline | Dependency |
|-------|--------|----------|----------|------------|
| **Zo** | ‚úÖ Complete | N/A | Done | None |
| **Zo2** | üîÑ Phase 1 | **P0** | 1-2 weeks | None |
| **Trial Matching** | üìã Approved | **P0** | 3 days | None |
| **Food Validation** | ‚ö†Ô∏è Alignment | **P0** | This week | None |
| **MM Doctrines** | ‚ö†Ô∏è Hold | **P2** | Wait for others | After P0 complete |

---

## üö® CRITICAL REMINDERS

### **For All Agents**

1. **Mechanism Alignment ‚â† Outcome Prediction**
   - Say "mechanism alignment score" not "efficacy score"
   - Say "pathway targeting" not "response probability"
   - Say "biologically appropriate" not "clinically proven"

2. **Validate Before Optimize**
   - Don't tune weights until you know the formula can work
   - Checkpoint after each phase
   - Know when to pivot

3. **Honest Communication**
   - Document limitations
   - Acknowledge what's unvalidated
   - Be proud of what we built, honest about what it does

4. **Independent Workstreams**
   - Zo2's outcome calibration is separate from mechanism fit ranking
   - Food validation is companion to drug recs, not replacement
   - Trial matching doesn't need to wait for Zo2

---

## üë• MASTER AGENT COORDINATION

### **Executive Summary**

We have **5 active workstreams** that need coordination:

| Priority | Agent | Task | Status | Timeline |
|----------|-------|------|--------|----------|
| 1 | **Zo2** | S/P/E Outcome Calibration | üîÑ Phase 1 Ready | 1-2 weeks |
| 2 | **Trial Matching** | Mechanism Fit + Resistance | üìã Approved | 3 days |
| 3 | **Food Validation** | Nutritional Support | ‚ö†Ô∏è Alignment Needed | 1 day |
| 4 | **Zo** | MBD4+TP53 Analysis | ‚úÖ Complete | Done |
| 5 | **MM Doctrines** | TCell/TCF1/TLS/TOX | ‚è∏Ô∏è On Hold | After 1-3 |

### **The Strategic Picture**

```
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ                    PRECISION ONCOLOGY PLATFORM                       ‚îÇ
‚îú‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î§
‚îÇ                                                                      ‚îÇ
‚îÇ  Patient Data ‚Üí S/P/E Framework ‚Üí Drug Efficacy (Zo, Zo2)           ‚îÇ
‚îÇ        ‚îÇ              ‚îÇ                                              ‚îÇ
‚îÇ        ‚îÇ              ‚îú‚îÄ‚îÄ‚Üí Mechanism Alignment ‚úÖ (works)            ‚îÇ
‚îÇ        ‚îÇ              ‚îî‚îÄ‚îÄ‚Üí Outcome Prediction ‚ùì (Zo2 testing)       ‚îÇ
‚îÇ        ‚îÇ                                                             ‚îÇ
‚îÇ        ‚îú‚îÄ‚îÄ‚Üí Trial Matching (Agent 2) ‚îÄ‚îÄ‚îÄ‚Üí Ranked Trials              ‚îÇ
‚îÇ        ‚îú‚îÄ‚îÄ‚Üí Resistance Prediction (Agent 2) ‚îÄ‚îÄ‚îÄ‚Üí Risk Signals        ‚îÇ
‚îÇ        ‚îú‚îÄ‚îÄ‚Üí Food Recommendations (Agent 3) ‚îÄ‚îÄ‚îÄ‚Üí Nutritional Support  ‚îÇ
‚îÇ        ‚îî‚îÄ‚îÄ‚Üí MM Doctrines (Agent 4) ‚îÄ‚îÄ‚îÄ‚Üí TCell/TLS/TOX ‚è∏Ô∏è ON HOLD    ‚îÇ
‚îÇ                                                                      ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
```

### **Priority 1: Zo2 - S/P/E Outcome Calibration**

**Goal**: Improve r=0.037 correlation to r=0.15-0.25

**Status**: üîÑ Phase 1 Ready

**What to Do**:
1. Execute Phase 1 (biomarker integration)
2. Run checkpoint analysis (r before/after)
3. If r > 0.10 ‚Üí Proceed to Phase 2
4. If r < 0.10 ‚Üí STOP and investigate

**Realistic Targets** (manager-adjusted):
- Phase 1: r=0.05-0.10
- Phase 2: r=0.10-0.20
- Phase 3: r=0.15-0.25

**Key Principle**: Validate before optimize.

---

### **Priority 2: Trial Matching Agent**

**Goal**: Wire mechanism fit to trial search + enhance resistance prediction

**Status**: üìã Approved to Start

**What to Do**:
1. Day 1: Wire mechanism fit to `trials_agent.py` (3-4h)
2. Day 2: Enhance resistance prophet with mechanism breakdown (3-4h)
3. Day 3: Create validation scripts (6-8h)

**Success Thresholds** (MVP):
- Top-3 accuracy: ‚â•0.70
- MRR: ‚â•0.65
- High risk AUROC: ‚â•0.65

**Key Principle**: Independent of Zo2.

---

### **Priority 3: Food Validation Agent**

**Goal**: Align terminology and add honest framing

**Status**: ‚ö†Ô∏è Alignment Needed (95% complete)

**What to Do**:
1. Rename `efficacy_score` ‚Üí `alignment_score`
2. Add limitations section to documentation
3. Revise "precision medicine-grade" claim
4. Add frontend disclaimer

**Time**: 1 day

**Key Principle**: Same rules as drugs - mechanism alignment, not outcome prediction.

---

### **Priority 4: Zo - MBD4+TP53 Analysis**

**Goal**: Mechanism alignment for rare case

**Status**: ‚úÖ Complete

**What Was Delivered**:
- Pathway vulnerabilities identified (DDR: 1.0, TP53: 0.8)
- Mechanism-aligned drugs found (PARP #1-3, Platinum #4)
- Mechanism vectors computed (DDR: 1.4)
- 6 P0 blockers fixed

**Key Principle**: Mechanism alignment works. Outcome prediction is separate (Zo2).

---

### **Priority 5: MM Doctrines Agent**

**Goal**: TCell/TCF1/TLS/TOX endpoints

**Status**: ‚è∏Ô∏è On Hold

**Why On Hold**:
1. Scope is massive (18 endpoints, 24 weeks)
2. Many external dependencies (CIBERSORT, NetMHCpan, spatial data)
3. Other agents need to finish first
4. No MVP definition

**What to Do Before Starting**:
1. Wait for Zo2/Trial Matching/Food Validation to complete
2. Define 2-week MVP (ONE proxy classifier)
3. Create known biology test suite first
4. Checkpoint after first classifier before expanding

---

### **Coordination Rules**

**Rule 1: Sequential, Not Parallel (for now)**
- Don't start MM Doctrines until Zo2/Trial Matching/Food Validation are done.

**Rule 2: Checkpoint Before Expanding**
- Every agent must checkpoint before expanding scope:
  - Zo2: r > 0.10 before Phase 2
  - Trial Matching: MVP thresholds before enhancement
  - MM Doctrines: First classifier before second

**Rule 3: Same Language**
- All agents use consistent terminology:
  - ‚úÖ "Mechanism alignment score"
  - ‚ùå "Efficacy score" (implies outcome prediction)
  - ‚úÖ "Biological plausibility"
  - ‚ùå "Clinical validation" (unless actually validated)

**Rule 4: Honest Framing**
- All agents must add limitations:
  - "These are mechanism-aligned recommendations"
  - "Not validated for outcome prediction"
  - "Decision support, not decision making"

---

### **This Week's Actions**

| Day | Agent | Action |
|-----|-------|--------|
| Mon | Zo2 | Start Phase 1 (biomarker integration) |
| Mon | Trial Matching | Start Day 1 (mechanism fit wiring) |
| Mon | Food Validation | Make alignment changes |
| Tue | Trial Matching | Day 2 (resistance enhancement) |
| Wed | Trial Matching | Day 3 (validation scripts) |
| Thu | Zo2 | Run Phase 1 checkpoint |
| Fri | MM Doctrines | Create test suite (if others done) |

---

## üìÅ CONSOLIDATED FROM

1. `STRATEGIC_DIRECTION.md` - AYESHA & S/P/E outcome calibration guidance
2. `STRATEGIC_GAP_ANALYSIS_BENCHMARK_VS_MBD4.md` - Gap analysis between benchmark and MBD4 vision
3. `STRATEGIC_REVIEW_MECHANISM_TRIAL_MATCHING.md` - Trial matching review
4. `STRATEGIC_REVIEW_FOOD_VALIDATION.md` - Food validation system review
5. `STRATEGIC_REVIEW_MM_DOCTRINES.md` - MM Doctrines review
6. `MASTER_AGENT_COORDINATION.md` - Master agent coordination and priorities

**All source documents archived to `.cursor/ayesha/archive/`**

---

**The righteous path: Validate, checkpoint, decide. Don't optimize blind. Be honest about what we're delivering.**

